Key Highlights On October 5, 2026, Cathie Wood’s ARK Invest divested 90,713 shares of Twist Bioscience, totaling approximately $17.1 million. The investment firm acquired 1,482,357 shares of
Cathie Wood’s [[LINK_START_1]]ARK Invest[[LINK_END_1]] executed multiple portfolio adjustments throughout its exchange-traded funds on Monday, October 5, 2026. Trade disclosure documents were published by the firm the following Tuesday morning.
Through its ARKK and ARKG funds, ARK divested 90,713 shares of Twist Bioscience. The transaction generated approximately $17.1 million in proceeds.
The October sale marks ARK’s second disposition of Twist Bioscience holdings this month. Previously, the investment manager offloaded 46,931 shares on September 29.
The investment firm purchased 1,482,357 shares of Recursion Pharmaceuticals. This acquisition, executed through the ARKK and ARKG funds, totaled approximately $6.1 million.
Recursion Pharmaceuticals, Inc., RXRX
Recursion Pharmaceuticals operates as a biotechnology enterprise leveraging artificial intelligence technology for pharmaceutical discovery. The company’s stock price climbed more than 16% during Monday’s trading session.
The biotech firm recently announced an extension of its data-licensing partnership with Tempus, now running through 2029. Market analysts maintain a consensus 12-month price objective of $7.22 for Recursion shares, per Koyfin data.
Additionally, ARK accumulated 96,308 shares of Intellia Therapeutics. The transaction carried an estimated value of $1.18 million.
This purchase builds upon previous acquisitions. Since September 29, ARK has accumulated over 1,178,000 Intellia shares across multiple transactions.
Intellia currently awaits regulatory approval from the FDA for its primary therapeutic candidate, designed to treat hereditary angioedema. The agency’s determination is expected by March 10, 2027.
Investment bank Barclays recently initiated research coverage on Intellia with an “Underweight” recommendation. The firm established a price objective of $8, suggesting potential downside of 36% from present trading levels.
Through its ARKG fund, ARK also acquired 115,472 shares of Veracyte. This purchase represented approximately $5.29 million in capital deployment.
Veracyte recently disclosed Phase 3 clinical trial results. The findings demonstrated that its Decipher Prostate diagnostic test can effectively identify prostate cancer patients likely to benefit from combined hormone therapy and radiation treatment protocols.
Beyond Twist Bioscience, ARK liquidated positions in two additional portfolio companies on Monday.
The investment manager sold 27,277 shares of 10x Genomics. This divestment generated approximately $2.55 million.
ARK further reduced its holdings by selling 22,271 shares of CareDx. That transaction yielded roughly $1.5 million in proceeds.
Twist Bioscience stock advanced 8.7% during Monday’s session. The equity has appreciated more than 60% throughout the preceding month.
Market observers attribute the recent rally to the company’s synthetic-DNA technology platform. Twist maintains a collaborative arrangement supporting Eli Lilly’s TuneLab AI-powered drug-discovery initiative.
10x Genomics equity climbed 4.5% on Monday and has surged more than 48% over the past month. CareDx shares gained 4% Monday, touching their highest valuation in over four years.
Through its ARKG fund alone, ARK has liquidated approximately $6 million in Twist Bioscience holdings during recent weeks. The firm maintains its practice of publishing daily trading activity each morning.
The post ARK Invest Acquires $6.1 Million Stake in Recursion Pharmaceuticals (RXRX) While Divesting Twist Bioscience appeared first on Blockonomi.
